(0.26%) 5 113.26 points
(0.33%) 38 367 points
(0.33%) 15 980 points
(-1.50%) $82.59
(5.25%) $2.02
(0.32%) $2 354.70
(0.17%) $27.58
(3.94%) $958.45
(-0.22%) $0.933
(-0.35%) $10.99
(-0.53%) $0.796
(1.68%) $93.41
-4.01% HKD 33.50
Live Chart Being Loaded With Signals
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 1.40M |
Średni wolumen | 1.53M |
Kapitalizacja rynkowa | 9.34B |
EPS | HKD0 ( 2024-03-25 ) |
Następna data zysków | ( HKD0 ) 2024-06-25 |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -22.64 |
ATR14 | HKD0.0510 (0.15%) |
Wolumen Korelacja
Keymed Biosciences Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Keymed Biosciences Inc. Korelacja - Waluta/Towar
Keymed Biosciences Inc. Finanse
Annual | 2023 |
Przychody: | HKD354.10M |
Zysk brutto: | HKD317.22M (89.59 %) |
EPS: | HKD-1.370 |
FY | 2023 |
Przychody: | HKD354.10M |
Zysk brutto: | HKD317.22M (89.59 %) |
EPS: | HKD-1.370 |
FY | 2022 |
Przychody: | HKD100.06M |
Zysk brutto: | HKD97.48M (97.42 %) |
EPS: | HKD-1.180 |
FY | 2021 |
Przychody: | HKD110.27M |
Zysk brutto: | HKD93.07M (84.40 %) |
EPS: | HKD-14.34 |
Financial Reports:
No articles found.
Keymed Biosciences Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej